Noxopharm patent applications relate to the form in which any isoflavonoid drug appears in the blood after rectal administration. These are not composition of matter patents relating to a particular molecule.
All lapsed or existing NRT/MEIP patents are irrelevant. The use of a suppository as cited in those patents also is irrelevant (a) because that was never reduced to practice, and (b) the production of the pro-drug form (idronoxil-C) is the critical bit of IP. Without that pro-drug form, the drug would not work.
This is patent 101 for anyone purporting to be an expert.
NOX announced on 10 April 2017 that it had filed a patent application for Idronoxil-C, a novel form of Idronoxil. This application has not yet entered the public domain, so any suggestion that NOX will not get patent protection for Idronoxil-C is based on ignorance.
Idronoxil-C
Add NOX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
9.9¢ |
Change
0.000(0.00%) |
Mkt cap ! $29.22M | |||
| Open | High | Low | Value | Volume |
| 10.0¢ | 10.5¢ | 9.9¢ | $4.773K | 48.10K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 20574 | 9.9¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 11.0¢ | 38542 | 2 |
View Market Depth
| Last trade - 16.10pm 29/11/2024 (20 minute delay) ? |
| NOX (ASX) Chart |
